Result of AGM

RNS Number : 4217J

Tissue Regenix Group PLC

26 April 2022

 

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Result of AGM

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that at the AGM held earlier today, all resolutions were duly passed on a show of hands.

The results of the poxy are set out below:

Resolution		In favour	%	Against	%	Withheld
1	Ordinary	3,096,432,946	99.87	4,000,000	0.13	859,285
2	Ordinary	3,091,355,706	99.71	9,104,066	0.29	832,459
3	Ordinary	3,096,355,706	99.87	4,104,066	0.13	832,459
4	Ordinary	3,091,355,706	99.71	9,104,066	0.29	832,459
5	Ordinary	3,091,355,706	99.71	9,104,066	0.29	832,459
6	Ordinary	3,091,355,706	99.71	9,104,066	0.29	832,459
7	Ordinary	3,091,355,706	99.71	9,104,066	0.29	832,459
8	Ordinary	3,096,379,267	99.87	4,080,505	0.13	832,459
9	Ordinary	3,096,379,267	99.87	4,080,505	0.13	832,459
10	Ordinary	3,090,580,199	99.68	9,826,573	0.32	885,459
11	Special	3,059,344,373	98.68	41,062,399	1.32	885,459
12	Special	3,085,499,489	99.49	15,789,742	0.51	3,000

NB: Percentage of Votes case excludes Withheld votes

The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 15 March 2022

For more information:

Tissue Regenix Group plc David Cocke, Chief Financial Officer	www.tissueregenix.com Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Nick Harland	Tel:  [phone]
Walbrook PR Ltd Alice Woodings / Lianne Applegarth	Tel: [phone] [e-mail]

About Tissue Regenix (www.tissuergenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs such as in sports medicine, foot and ankle, and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.

 

END

 

 

RAGSEMFIMEESEFL